Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis.
We determined whether positive ANA was related to response to rIFNss-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI outcome during short-term (6 months) and long-term (24 months) treatment period was not statistically different between the groups. Therefore, the response to IFNbeta-1a seems not to be influenced by ANA occurrence either before or during treatment. When the analysis was extended to other autoantibodies (i. e. antithyroid, anticardiolipin) similar results were obtained.
Ciccarelli
O
O
Department of Neurological Sciences, University of Rome 'La Sapienza', Rome, Italy.
Bagnato
F
F
Mainero
C
C
Salvetti
M
M
Paolillo
A
A
Gasperini
C
C
Bastianello
S
S
Pozzilli
C
C
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008279:Magnetic Resonance Imaging; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000974:Antibodies, Antinuclear; D016899:Interferon-beta; D000068556:Interferon beta-1a